Altimmune (NASDAQ:ALT) Coverage Initiated by Analysts at William Blair

William Blair began coverage on shares of Altimmune (NASDAQ:ALT) in a research report report published on Friday, Marketbeat reports. The brokerage issued a market perform rating on the stock.

ALT has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a report on Wednesday, February 5th. Stifel Nicolaus assumed coverage on Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 target price on the stock. Finally, UBS Group assumed coverage on Altimmune in a research note on Tuesday, November 12th. They issued a “buy” rating and a $26.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Altimmune has a consensus rating of “Moderate Buy” and a consensus price target of $20.83.

Altimmune Price Performance

Shares of NASDAQ:ALT opened at $6.65 on Friday. The business’s 50-day moving average is $6.85 and its 200 day moving average is $7.19. Altimmune has a 1 year low of $5.28 and a 1 year high of $14.05. The firm has a market capitalization of $472.98 million, a P/E ratio of -4.29 and a beta of 0.19.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. On average, analysts expect that Altimmune will post -1.35 EPS for the current year.

Hedge Funds Weigh In On Altimmune

Hedge funds have recently bought and sold shares of the business. Larson Financial Group LLC purchased a new position in Altimmune during the third quarter worth approximately $31,000. SBI Securities Co. Ltd. acquired a new position in shares of Altimmune during the fourth quarter valued at approximately $45,000. Virtus ETF Advisers LLC acquired a new position in shares of Altimmune during the fourth quarter valued at approximately $60,000. Cullen Frost Bankers Inc. acquired a new stake in shares of Altimmune in the fourth quarter valued at approximately $72,000. Finally, Sunbelt Securities Inc. increased its holdings in shares of Altimmune by 356.8% in the fourth quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company’s stock valued at $79,000 after purchasing an additional 8,470 shares during the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.